title: Eli Lilly: Outstanding Orforglipron Data Reinforces Value Proposition
source: SeekingAlpha
date: 2025-10-15
url: https://finnhub.io/api/news?id=11a4e2da9a2a24750ae447ed7afd4c08bfb961e75ba0f601e7de1aeaee6f88e3
Eli Lilly and Company's strong Phase 3 diabetes drug results boost its GLP-1 franchise. Click for my updated look at LLY stock following the latest data.
